NCT04673734 is a clinical trial of myelin sensitive MRI scan in Myelin Integrity, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT04673734?

NCT04673734 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT04673734?

Interventions in NCT04673734: myelin sensitive MRI scan.

What condition does NCT04673734 study?

NCT04673734 studies Myelin Integrity.

Is NCT04673734 still recruiting?

NCT04673734 is currently completed. Last updated 15 December 2021.

Last reviewed 2021-12-15 · How we verify

NCT04673734

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Scan-rescan Reproducibility of Myelin Sensitive MRI Techniques

Completed Last updated 15 December 2021

What this trial tests

trial testing myelin sensitive MRI scan in Myelin Integrity in 13 participants. Completed in 30 September 2021.

Timeline

5 February 2021

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	13
Start date	5 February 2021
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across Switzerland

Drugs / interventions tested

myelin sensitive MRI scan

Conditions studied

Myelin Integrity — all drugs for Myelin Integrity →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 80, any sex, with Myelin Integrity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to assess the variation in the measurements of myelin sensitive MRI techniques in both white and grey matter in the brain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04673734 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 15 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing